
BioStem Technologies Inc.
BSEM | NASDAQ
$1.22
+$0.10 (+8.93%)
Nov 2, 2026, 12:15 PM ET · Market open
Company Profile
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Key Executives
| Name | Position |
|---|---|
| Jason Matuszewski | Chief Executive Officer, President, Secretary & Chairman |
| Andrew Vanvurst | Chief Operating Officer & Director |
| Brandon Poe | Chief Financial Officer |
| Barry J. Hassett | Chief Commercial Officer |
| David Woynarowski | Chief Medical Officer |
| Irmgard Huber | International Medical Advisor & Interim Chief Medical Officer |
| Jeff Humke | Vice President of Human Resources |
| Katherine Gorrell | Chief Legal & Compliance Officer |
| Larry Jones | Chief Revenue Officer |
| Michael Fortunato | Chief Accounting Officer |
| Noah Agron | Vice President of Corporate Finance & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 02, 2026 | S-1 | Filing |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 29, 2026 | EFFECT | Filing |
| Sep 29, 2026 | 424B3 | Filing |
| Sep 21, 2026 | D | Filing |
| Sep 18, 2026 | S-1 | Filing |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
BioStem Technologies Inc.

| Country | United States |
| IPO Date | Mar 17, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Jason Matuszewski |
Contact Details
4901 Northwest 17th Way Fort Lauderdale,
Florida 33309 United States
Stock Details
| Ticker Symbol | BSEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658678 |
| CUSIP Number | 090684200 |
| ISIN Number | US0906842002 |
| SIC Code |
Add to Watchlist
Select watchlists to add or remove BSEM